Literature DB >> 23089369

Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study.

Christina M Parrinello1, Alan L Landay, Howard N Hodis, Stephen J Gange, Philip J Norris, Mary Young, Kathryn Anastos, Phyllis C Tien, Xiaonan Xue, Jason Lazar, Lorie Benning, Russell P Tracy, Robert C Kaplan.   

Abstract

OBJECTIVE: We examined serum lipids in association with carotid artery intima-media thickness (CIMT) in HIV-infected and HIV-uninfected women.
METHODS: In 2003-4, among 1827 Women's Interagency HIV Study participants, we measured CIMT and lipids (high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC), non-HDL-c). A subset of 520 treated HIV-infected women had pre-1997 lipid measures. We used multivariable linear regression to examine associations between lipids and CIMT.
RESULTS: In HIV-uninfected women, higher TC, LDL-c and non-HDL-c were associated with increased CIMT. Among HIV-infected women, associations of lipids with CIMT were observed in treated but not untreated women. Among the HIV-infected women treated in 2003-4, CIMT was associated both with lipids measured a decade earlier in infection, and with late lipid measurements.
CONCLUSION: Among HIV-infected women, hyperlipidemia is most strongly associated with subclinical atherosclerosis in treated women. Among treated women, the association appeared strongest early in the disease course.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089369      PMCID: PMC3696584          DOI: 10.1016/j.atherosclerosis.2012.09.035

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  15 in total

1.  Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

Authors:  Jim Young; Rainer Weber; Martin Rickenbach; Hansjakob Furrer; Enos Bernasconi; Bernard Hirschel; Philip E Tarr; Pietro Vernazza; Manuel Battegay; Heiner C Bucher
Journal:  Antivir Ther       Date:  2005

2.  Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.

Authors:  Steven A Grover; Louis Coupal; Norbert Gilmore; Jayanti Mukherjee
Journal:  Am J Cardiol       Date:  2005-03-01       Impact factor: 2.778

3.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Authors:  H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen
Journal:  Ann Intern Med       Date:  2001-12-04       Impact factor: 25.391

4.  Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients.

Authors:  Bela F Asztalos; Ernst J Schaefer; Katalin V Horvath; Caitlin E Cox; Sally Skinner; Jul Gerrior; Sherwood L Gorbach; Christine Wanke
Journal:  Atherosclerosis       Date:  2005-06-01       Impact factor: 5.162

5.  Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.

Authors:  S A Riddler; X Li; H Chu; L A Kingsley; A Dobs; R Evans; F Palella; B Visscher; J S Chmiel; Ar Sharrett
Journal:  HIV Med       Date:  2007-07       Impact factor: 3.180

6.  Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

Authors:  Kathryn Anastos; Dalian Lu; Qiuhu Shi; Phyllis C Tien; Robert C Kaplan; Nancy A Hessol; Steven Cole; Cheryl Vigen; Mardge Cohen; Mary Young; Jessica Justman
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

7.  Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.

Authors:  Priscilla Y Hsue; Joan C Lo; Arlana Franklin; Ann F Bolger; Jeffrey N Martin; Steven G Deeks; David D Waters
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

8.  Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients.

Authors:  S Badiou; R Thiebaut; V Aurillac-Lavignolle; F Dabis; F Laporte; J P Cristol; P Mercie
Journal:  J Infect       Date:  2008-06-12       Impact factor: 6.072

9.  HIV infection and high density lipoprotein metabolism.

Authors:  Honor Rose; Jennifer Hoy; Ian Woolley; Urbain Tchoua; Michael Bukrinsky; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2007-12-04       Impact factor: 5.162

10.  Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.

Authors:  Robert C Kaplan; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Christina M Parrinello; Lorie Benning; Russell P Tracy
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

View more
  6 in total

1.  Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study.

Authors:  Christina M Parrinello; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Lorie Benning; Russell P Tracy; Robert C Kaplan
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

2.  Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Chin-Shang Li; Robert Kaplan; Jason Lazar; Dan Merenstein; Roksana Karim; Brad Aouizerat; Mardge Cohen; Kenneth Butler; Savita Pahwa; Igho Ofotokun; Adaora A Adimora; Elizabeth Golub; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-23       Impact factor: 8.311

3.  Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Chin-Shang Li; Robert Kaplan; Jason Lazar; Dan Merenstein; Roksana Karim; Brad Aouizerat; Mardge Cohen; Kenneth Butler; Savita Pahwa; Igho Ofotokun; Adaora A Adimora; Elizabeth Golub; Lars Berglund
Journal:  J Lipid Res       Date:  2018-07-16       Impact factor: 5.922

4.  The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study.

Authors:  Honor Rose; Hann Low; Elizabeth Dewar; Michael Bukrinsky; Jennifer Hoy; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2013-04-17       Impact factor: 5.162

5.  Echolucency of the carotid artery intima-media complex and intima-media thickness have different cardiovascular risk factor relationships: the Women's Interagency HIV Study.

Authors:  Molly Jung; Christina M Parrinello; Xiaonan Xue; Wendy J Mack; Kathryn Anastos; Jason M Lazar; Robert H Selzer; Anne M Shircore; Michael Plankey; Phyllis Tien; Mardge Cohen; Stephen J Gange; Howard N Hodis; Robert C Kaplan
Journal:  J Am Heart Assoc       Date:  2015-02-19       Impact factor: 5.501

Review 6.  Hypertension and human immunodeficiency virus: A paradigm for epithelial sodium channels?

Authors:  Katongo H Mutengo; Sepiso K Masenga; Naome Mwesigwa; Kaushik P Patel; Annet Kirabo
Journal:  Front Cardiovasc Med       Date:  2022-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.